Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.